Sensidose AB - søkeresultat

Den europeiske union - norsk - EMA (European Medicines Agency)

iressa

astrazeneca ab - gefitinib - karsinom, ikke-småcellet lunge - antineoplastiske midler - iressa er indisert for behandling av voksne pasienter med lokalt avansert eller metastatisk ikke-liten celle lunge kreft med aktiverende mutasjoner av epidermal vekst-faktor-reseptor tyrosin kinase.

Den europeiske union - norsk - EMA (European Medicines Agency)

fluenz tetra

astrazeneca ab - a/darwin/9/2021 (h3n2) - like strain (a/norway/16606/2021, medi 355293) / a/victoria/2570/2019 (h1n1)pdm09 - like strain (a/victoria/1/2020, medi 340505) / b/austria/1359417/2021 - like strain (b/austria/1359417/2021, medi 355292) / b/phuket/3073/2013 - like strain (b/phuket/3073/2013, medi 306444) - influensa, human - influensa vaksiner, influensa, levende svekket - prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. bruk av fluenz tetra bør være basert på offisielle anbefalinger.

Den europeiske union - norsk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influensavirus (levende dempet) av følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influensa, human - vaksiner - profylakse av influensa i en offisielt erklært pandemisk situasjon hos barn og ungdom fra 12 måneder til under 18 år. pandemisk influensa h5n1-vaksine astrazeneca skal være brukt i samsvar med offisielle veiledning.

Den europeiske union - norsk - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - karsinom, ikke-småcellet lunge - andre cytostatika, protein kinase hemmere - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.